Freezing of Gait, Parkinson Disease, Spinal Cord Stimulation
Conditions
Keywords
Spinal cord stimulation, Freezing of gait, Parkinson Disease
Brief summary
Spinal cord stimulation (SCS) has proven to be effective for pain that is unresponsive to medication. This technique involves an anesthesiologist or a neurosurgeon placing stimulation electrodes at the thoracic vertebrae to provide pain relief. Although SCS is not currently a standard treatment for patients with Parkinson's disease, recent studies have shown that Parkinson's patients who experience intolerable pain and undergo SCS treatment not only experience pain relief but also show improvements in gait and other Parkinson's symptoms. Therefore, the investigators aim to use temporary, minimally invasive SCS electrodes to help patients with nrFOG (non-responsive Freezing of Gait) improve their stability and reduce their risk of falls.
Interventions
DEVICESCS electrode stimulation 3
60Hz/300us
DEVICESCS electrode stimulation 1
300Hz/300us
DEVICESCS electrode stimulation 2
130Hz/300us
Sponsors
National Taiwan University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Age:40-85 years old. * Patients with primary Parkinson's disease who have been diagnosed by a movement disorder specialist for more than 5 years. Although they have a clear response to drugs, they have a frozen gait that cannot be controlled by drugs. Lower limb pain may be present with or without Parkinson's non-motor symptoms. * No other secondary gait problems.
Exclusion criteria
* Atypical Parkinson's disease. * Patients with spinal cord injuries. * Medication-controlled frozen gait. * It is expected that there are lesions near the implantation area causing spinal canal stenosis or myelopathy (can be ruled out by MRI). * It is expected that the implantation area has undergone previous surgery or there is infection near the implantation area, which may affect the success rate of implantation or increase concerns about complications (such as severe extraspinal adhesion, or spinal cord damage in previous surgeries). * People with abnormal coagulation function (such as hemophilia patients) or those who have been controlled by long-term use of antithrombotic drugs and cannot stop taking them in a short period of time. * CDR (Clinical Dementia Rating Scale) ≧2. 8. Those who are allergic to developer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gait parameters --- stride time [second] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- cadence [steps/minute] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- velocity [km/hour] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- foot rotation [degtree] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- step length [cm] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- stride length [cm] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- step width [cm] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- stance phase [%] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- swing phase [%] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- double stance phase [%] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
| Gait parameters --- step time [second] | Day 0, Day 2, Day 3, Day 4, and Day 7 | (1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical score | Day 0, Day 2, Day 3, Day 4, and Day 7 | 1. MDS-UPDRS part III (motor examination) 2. Score: 0-72 (Higher scores means worse.) |
| Clinical Scale | Day 0, Day 2, Day 3, Day 4, and Day 7 | 1. Tinetti Gait Analysis 2. Score: 0-16 (Higher scores means better.) |
Countries
Taiwan
Contacts
Primary ContactKai-Hsiang Chen, M.D.
Outcome results
None listed